FOR IMMEDIATE RELEASE
Wednesday, April 10, 2013
Contact: Megan Archer, Assistant to the Dean, College of Health Professions 304-696-2624
Marshall University cytotechnology program receives continuing accreditation
HUNTINGTON, W.Va. – The Marshall University School of Cytotechnology at Cabell
Huntington Hospital has been awarded continuing accreditation from the
Commission on Accreditation of Allied Health Education Programs (CAAHEP).
The program was originally accredited in 1969 and has been surveyed every five to seven years since that time. The next evaluation of the program will include an on-site review and is scheduled to occur no later than 2020.
Margene Smith, program director of Cytotechnology, said the accreditation process takes approximately six months to complete and would not be possible without the continued support of Marshall University and Cabell Huntington Hospital.
“Marshall provides the three years of on-campus classes and Cabell Huntington provides the clinical training year,” Smith said. “Together, the institutions offer a program, which results in a Bachelor of Science degree in cytotechnology for the student.”
Smith said through the hospital and cancer center, they are able to offer training with state of the art procedures.
“The graduates of this school are employed in prestigious institutions all over the country,” Smith said. “Students must graduate from an accredited institution in order to sit for their board exam. Without passing this exam, they cannot be employed as a cytotechnologist.”
Dr. Michael W. Prewitt, dean of the College of Health Professions, said he commends his colleagues for their commitment to this program.
“As demonstrated by the efforts to receive program accreditation, we can see continuous improvement for health professions education at Marshall University,” Prewitt said.
According to the American Society for Cytotechnology, cytotechnologists study cells and “work in collaboration with pathologists to diagnose benign and infectious processes, precancerous lesions and malignant disease.” Currently, there are only 31 accredited cytotechnology programs in the U.S.